Gonorrhea: Treatment and management considerations for the male patient

Brian Dalke, Timothy Ivers, Karen K. O’Brien, Shana Castillo, Eric Hoie, Kimberley J. Begley

Research output: Contribution to specialist publicationArticle

Abstract

Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

Original languageEnglish (US)
Pages41-44
Number of pages4
Volume41
No8
Specialist publicationU.S. Pharmacist
StatePublished - Aug 1 2016

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Gonorrhea: Treatment and management considerations for the male patient'. Together they form a unique fingerprint.

  • Cite this

    Dalke, B., Ivers, T., O’Brien, K. K., Castillo, S., Hoie, E., & Begley, K. J. (2016). Gonorrhea: Treatment and management considerations for the male patient. U.S. Pharmacist, 41(8), 41-44.